US Retinal Specialis
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
19 mars 2024 14h20 HE | Spherix Global Insights
EXTON, PA, March 19, 2024 (GLOBE NEWSWIRE) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising...
Logo.png
Gene Therapies In Ophthalmology Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
19 févr. 2024 13h00 HE | DelveInsight Business Research LLP
New York, USA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Gene Therapies In Ophthalmology Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment |...
Parkinson’s Disease
Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
16 févr. 2024 10h40 HE | Spherix Global Insights
EXTON, PA, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this...
market-digits.jpg
Gene Switch/Molecular Switch Market projected to reach USD 1.4 Billion by 2030, growing at a CAGR of 11.3% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study Richmond, Feb. 15, 2024 (GLOBE NEWSWIRE) -- According to a research report "Gene Switch/Molecular Switch Market”, by Product Type (CAR-T Cell Therapies, Gene Therapies, Others), Payment model...
Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease
01 juin 2023 05h09 HE | Rentschler Biopharma SE
Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...
NOVARTIS logo.jpg
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
19 mars 2023 19h00 HE | Novartis Pharma AG
Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll children (100%) in the presymptomatic intravenous...
MnM_logo_TM_JPG.JPG
Regenerative Medicine Market is Expected to Reach $40.6 Billion | MarketsandMarkets.
24 févr. 2023 07h30 HE | MarketsandMarkets Research Pvt. Ltd.
Chicago, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Regenerative medicine is an emerging field of medicine that is focused on using the body’s natural healing processes to repair and regenerate damaged...
Roots-Analysis-Logo.png
The CAR-T cell therapy market is projected to grow at an annualized rate of 23%, claims Roots Analysis
15 févr. 2023 10h00 HE | Roots Analysis
London, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Global CAR-T Cell Therapy Market (4th Edition), 2022-2035 ” report to its list of offerings. CAR-T cell...
nChain Partners With ATMPS Ltd. to Power Their World-Leading Cell and Gene Therapy Platform Hataali
06 déc. 2022 07h46 HE | nChain (957856)
ZUG, Switzerland, Dec. 06, 2022 (GLOBE NEWSWIRE) -- nChain, one of the largest global blockchain solutions companies, today announces its partnership with Hataali, the world-leading cell and gene...
Roots-Analysis-Logo.png
The NAMPT inhibitors market is projected to grow at an annualized rate of 15.08% during the period 2029-2040, claims Roots Analysis
03 nov. 2022 15h00 HE | Roots Analysis
London, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “NAMPT Inhibitors Market, 2022-2040” report to its list of offerings Cancer is one of the leading causes of...